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Key statements: 
1 Long-term maintenance on a HF diet only slightly attenuates acute amylin action. 
2 Attenuation of amylin action seems more related to obesity than HF exposure.  
3 Acute amylin sensitivity is not reduced by chronic hyperamylinemia. 
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ABSTRACT 
Obesity results in the increased secretion of various hormones controlling food intake 
and body weight, such as leptin, and insulin; increased circulating levels of pancreatic 
amylin have also been described in obese humans and rodents. Because leptin-
resistance is e.g. present in diet-induced obese (DIO) rats, and because hyperleptinemia 
seems necessary for the full development of leptin resistance, we tested whether amylin 
sensitivity is inversely correlated with adiposity, such that DIO reduces the anorectic 
action of acute amylin. We also determined if hyperamylinemia leads to a change in 
amylin sensitivity. In the first experiment, rats were chronically exposed to a high fat (HF; 
60% fat) diet or fed standard chow for control. The anorectic response to amylin was 
tested on several occasions over a 14 week observation period. HF feeding led to the 
expected increase in body adiposity; the response to an acute amylin injection (5 – 50 
µg/kg s.c.) was unaltered for 10 weeks of HF feeding. Even after 12 weeks on a HF diet 
which clearly caused obesity, acute administration of amylin (5µg/kg, s.c.) was still able 
to suppress food intake, although the suppression was not statistically significant. 
Further experiments using additional doses of amylin will be necessary to demonstrate 
possible amylin resistance after HF feeding or in DIO rats. In the second experiment, we 
tested more specifically whether hyperamylinemia that may e.g. result from HF feeding 
and subsequent obesity, reduces the sensitivity of the amylin signaling system. To avoid 
confounding factors, we chronically infused lean chow fed rats with amylin (5 or 10 
µg/kg/day s.c.) to elevate their plasma amylin concentration to levels observed in obese 
rats (30 – 40 pM). In the absence of obesity, hyperamylinemia did not lead to a reduced 
sensitivity to acute amylin (5 – 20 µg/kg s.c.) injections; acute amylin reduced eating 
similarly in all groups of rats. Overall, we concluded that direct diet effects by short term 
exposure to HF appear to be of little importance for amylin sensitivity; further, long-term 
maintenance on a HF diet and the resulting obesity only slightly attenuated the anorectic 
response to acute amylin. Because we observed no marked changes in amylin 
sensitivity in lean, chow fed rats with induced hyperamylinemia, amylin receptor 
downregulation in chronic hyperamylinemia does not seem to occur. 
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1. INTRODUCTION 
Obesity typically results in increased secretion of various hormones controlling food 
intake and body weight, such as leptin, and insulin [1, 2]; elevated circulating levels of 
these adiposity signals in obesity eventually results in the decreased peripheral and 
central sensitivity to leptin and insulin [3, 4], respectively, which only further potentiates 
the obese state. Leptin-resistance, for example, is present in diet-induced obese (DIO) 
mice and rats, and is thought to result from several factors including defective leptin 
receptor signaling and decreased leptin transport across the blood brain barrier 
[Reviewed in 5, 6].  It was also shown recently that hyperleptinemia is required for the 
full development of leptin resistance [7]. Obesity can also affect the sensitivity to 
satiation hormones, which control meal size, such as glucagon-like peptide-1 (GLP-1) 
and cholecystokinin (CCK) [8, 9].   
 
Increased circulating levels of amylin have also been described in obese humans and 
rodents (“tonic” increase) [10-12]. Amylin is a pancreatic hormone which buffers glucose 
flux during a meal by decreasing food intake, gastric emptying, and glucagon secretion. 
Thus, in response to nutrient ingestion, circulating amylin concentrations rise rapidly 
within minutes after meal onset (“phasic” increase), peak within 60 min, and return to 
baseline by 120 min [13]. When administered exogenously (peripherally or centrally), 
acute amylin dose-dependently decreases food intake, causing a decrease in meal size 
though having no effect on the intermeal interval [14, 15]. Furthermore, the decrease in 
meal size is not a result of an aversive or toxic effect of amylin [14, 16].  
 
Some rodent models of obesity (e.g. ob/ob and MC4Rko mice, fa/fa rats) require higher 
doses of the amylin receptor agonist, salmon calcitonin (sCT) to reduce eating [17], 
suggesting that obesity may attenuate amylin sensitivity.  Previous pilot work has also 
indicated that high circulating amylin levels may reduce the ability of amylin to slow 
gastric emptying [18]. Furthermore, clinical tests report that higher doses of the amylin 
analog, pramlintide, are necessary to promote weight loss in type 2 versus type 1 
diabetics, suggesting that amylin deficiency, as found in type 1 diabetics, may perhaps 
increase the efficacy of exogenous amylin [19].  
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Based on these data, we tested whether amylin sensitivity is inversely correlated with 
adiposity, such that diet-induced obesity reduces the anorectic action of acute amylin. 
We also determined if factors that cause obesity, such as consumption of a high-fat diet, 
or that are associated with obesity, such as hyperamylinemia, can lead to a change in 
amylin sensitivity, independently of obesity.   
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2. MATERIALS AND METHODS 
2.1 Experimental animals  
Sprague-Dawley rats (initial body weight 240-300g; Harlan NM Horst, the Netherlands) 
were used for all experiments; some animals served as a model for diet-induced obesity 
(DIO). The animals were individually housed in hanging, stainless steel wire-mesh cages 
and were maintained in a temperature-controlled environment (21 2°C), on a 12/12h 
light-dark cycle. Water and food were accessible ad libitum, unless otherwise indicated. 
All rats were habituated to the housing conditions for at least one week prior to the start 
of an experiment. During habituation, rats were handled daily, and they were also 
allowed 30 min access to a common, enriched environment to play.  All experiments 
were approved by the Veterinary Office of the Canton of Zürich, Switzerland. 
2.2 Experimental Diets 
During the acclimatization phase of each experiment and during the entire duration of 
the second experiment, rats were allowed ad libitum access to standard pelleted chow 
(Diet 3430, Provimi Kliba AG, Kaiseraugst, Switzerland; energy content: 13 kJ/g, protein 
(w/w): 21%, carbohydrates: 39.8%, fat: 5%), except where noted. In experiment one, 
DIO was induced in one group of rats by providing ad libitum access to a pelleted high 
fat diet (60% energy from fat; Diet 2127, Provimi Kliba AG, Kaiseraugst, Switzerland; 
energy content: 22 kJ/g, protein (w/w): 26%, carbohydrates: 1%, fat: 38.0%). Standard 
chow was also fed to control animals in this experiment; the third group of rats in 
experiment one also received chow but was restricted to 80% of ad libitum intake. 
2.3 Amylin 
 
Amylin (Bachem AG; Bubendorf, Switzerland) was dissolved in 0.9% NaCl (Fresenius 
Kabi AG, Stans, Switzerland) in various concentrations, depending on the experiment 
(see below). 
 
2.4 Osmotic minipump implantation 
Amylin was chronically administered peripherally by subcutaneous osmotic minipumps 
with a mean pumping rate of 1.0µl per hour for seven days (alzet, Model 2001, Durect 
Corporation, Cupertino USA). On the morning of implantation, the minipumps were filled 
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under sterile conditions with saline or amylin (total volume = 238µl/minipump, in doses 
described below). Rats were initially anesthetized by inhalation of 5% isoflurane 
(IsoFlo, Provet AG Lyssach, Switzerland), then maintained on 2-3% isoflurane and 
placed on a heating pad to maintain body temperature during surgery. At the site of 
implantation, rats were shaved and the skin was disinfected with Betadine (Provet AG, 
Lyssach, Switzerland).  Under sterile conditions, a small incision was made between the 
scapulae and the minipump was subcutaneously implanted.  The wound was closed with 
interrupted cutaneous sutures.  
2.5 Blood Sampling 
Prior to blood sampling, rats were food deprived for the last 6 hrs of the dark phase. 
Immediately after being briefly anesthetized by inhalation of 5% isoflurane, rats were 
placed in a supine position and the tongue was extended from the mouth using a cotton-
tipped applicator.  One of the sublingual veins was punctured with a 20G needle, and 
blood was collected in a 500µl serum tube (Microvette, SARSTEDT, Nümbrecht, 
Germany) and mixed with 5µl of a Protease Inhibitor Cocktail (P2714, Sigma, Missouri, 
USA). The blood remained at room temperature for at least 30 minutes and then 
centrifuged for 10 minutes at 2500g.  Serum was then transferred to clean tubes and 
stored at - 20°C until use. 
2.6 Hormone Measurements 
 
Circulating levels of serum amylin, insulin and leptin were measured in duplicate by 
fluorescence immunoassay using the Rat Endocrine Panel Milliplex MAP kit from 
Millipore (Millipore Corporation, Billerica, MA, U.S.A.). Sensitivity of the assay was 0.32 
ng/mL for insulin, 6.2 pM for amylin, and 0.1 ng/mL for leptin.  Intraassay CVs were less 
than 10%. Data were analyzed by Bio-Plex Manager software versions 4.0 and 5.0 
(Bio-Rad Laboratories, Inc.) 
 
2.8 Body Composition Analysis 
Body adiposity was determined postmortem by computerized tomography (CT) using the 
La Theta LCT-100 scanner (Aloka, Tokyo, Japan). The X-ray source tube voltage was 
set at 50 kV with a constant 1 mA current. The frozen carcasses were placed supine in 
the holders with an inner diameter of 120mm. Abdominal scans were done between 
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vertebrae L1 and L6. Aloka software was used to estimate the volumes of adipose tissue, 
bone, air, and remaining tissue, using differences in X-ray density. Intra-abdominal 
(IAAT) and subcutaneous adipose tissue (SAT) were distinguished based on the 
detection of the abdominal muscle layers; in some cases, this automated classification 
required manual image-by-image correction. Whole-body IAAT and SAT were estimated 
using previously validated calculations [20, 21]. Total adiposity was calculated as the 
sum of whole-body IAAT and SAT mass. 
 
2.9 Description of Experiments One and Two 
2.9.1 Experiment One: Do diet and body composition influence the anorectic effect of 
amylin? 
The aim of the first experiment was to assess if the acute anorectic response to amylin is 
altered in rats chronically fed a high fat diet or food restricted, thus achieving a state of 
DIO or reduced body weight by chronic underfeeding. 
Following habituation, rats were divided into three randomized groups (7-8 rats/group). 
The control group was fed ad libitum with standard chow diet. A second group was fed 
ad libitum with the 60% HF diet to achieve DIO. A third group was maintained on chow, 
but restricted to 80% of the ad libitum intake of the chow-fed controls for 11 weeks; the 
total daily allotment of food was provided at dark onset. Starting at week 12, restricted 
rats were switched to the HF diet ad libitum for the remainder of the experiment.   
Over the course of the 14-week experiment, six feeding trials were performed, each 
testing the acute anorectic response to different doses of amylin at various points of HF 
feeding or food restriction. The timing and amylin dosing for the trials were as follows 
(also shown in Fig. 1A): Trial 1: week 2, 5g/kg; Trial 2: week 3, 20g/kg; Trial 3: week 6, 
20g/kg; Trial 4: week 7, 50g/kg; Trial 5: week 10, 50g/kg; Trial 6: week 12, 5g/kg. In 
all trials food was removed from the cages one hour before dark onset.  
In trials 1, 2, and 6, amylin or saline were administered subcutaneously immediately 
before dark onset, food was returned immediately after treatment, and energy intake 
was measured at 60 and 120min post-injection. After the completion of trials 1 and 2, we 
presumed that strong hunger, habituation and conditioning to dark-onset feeding 
prevented amylin-induced anorexia in the chronically restricted rats in these trials. 
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Because the goal of the study was to test if amylin sensitivity changes in lean 
respectively underweight rats, and not in hungry rats, in trials 3, 4, and 5, all rats were 
allowed to pre-feed for the first hour of the dark phase, following which amylin or saline 
was subcutaneously administered and energy intake measured at 60 and 120min. In 
trials 3 and 4, rats were given ad libitum access to their respective diet during the 60min 
pre-feeding phase. In trial 5, the amount of the food which was given to all rats in the 
pre-feeding phase was matched to the approximate caloric load that the chow control 
group had consumed in trials 3 and 4 (50 kJ).   
For all trials, food intake is depicted as energy intake (in kJ) to allow the comparison 
between standard chow and HF intake. All feeding trials were performed in a crossover 
manner within diet groups so that each rat received both saline and amylin treatments.   
Sublingual blood samples for hormone measurements were collected during weeks 9 
and 14. Following blood sampling in week 14, rats were euthanized via an overdose of 
pentobarbital (300mg/kg i.p.), and frozen prior to performance of CT scans to determine 
body composition. 
 
2.9.2 Experiment Two: Does chronic elevation of peripheral amylin levels induce a 
change in amylin sensitivity? 
To investigate if elevated basal levels of circulating amylin change the sensitivity to the 
acute anorectic action of amylin in non-obese rats, circulating basal amylin was clamped 
to different levels using osmotic minipumps. Two amylin doses (5 and 10µg/kg/day) were 
chosen based on pilot studies, on circulating levels of DIO rats observed in Experiment 1, 
and on published work [16, 22], and were compared to saline infused controls. 
For the duration of the experiment, rats were allowed ad libitum access to standard 
pelleted chow. The modified counterbalanced experiment was performed over three 
weeks, during which every animal received each combination of minipump infusate 
(saline, 5 or 10µg/kg/day amylin, s.c.), mimicking different levels of “tonic” amylin, and 
three acute injection (saline, 5 or 20µg/kg amylin, s.c.), mimicking the “phasic” meal 
induced release of amylin. To allow plasma amylin levels to equilibrate to the target 
concentration, the first of three feeding trials was administered approximately 72h 
following minipump implantation (corresponding to day 3 in Fig. 2A); trials 2 and 3 were 
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performed on days 5 and 7, respectively. For all feeding trials, saline or amylin was 
administered to non-fasted rats immediately before dark onset. Energy intake was 
measured 30, 60 and 120min following the treatment.  
On day 7 of each week, two hours following the completion of the third feeding trial and 
before the minipumps were exchanged, sublingual blood samples were taken to assess 
basal circulating amylin levels.  
 
2.10 Statistical Analysis 
All data are expressed as mean  SEM. Experiments performed in a crossover manner 
were analyzed using paired t-test, when appropriate. When more than two groups were 
compared, data were analyzed using one-way ANOVA, with Bonferroni’s post-hoc test 
used to determine differences between individual groups. A p-value <0.05 was 
considered to be statistically significant.  Statistical analyses were performed using 
GraphPad Prism (version 5.0, San Diego, CA, USA). 
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3. RESULTS 
3.1 Experiment One  
3.1.1 Development of DIO 
Baseline body weight was similar across groups (240-260g), with no significant 
differences at the start of the experiment. Figure 1A shows the average body weight of 
the three groups for the duration of the study. At the beginning of week 12 (day 77), the 
restricted rats were switched to the HF diet, which was then offered ad libitum for the 
remainder of the experiment.  
Comparison of the average body weights of the chow control group and the HF fed 
animals, demonstrates a demarcation between obese and non-obese rats, with a 
significant difference starting at week 9 and remaining significantly different for the 
duration of the observation period. Compared to the ad libitum chow and HF fed rats, the 
mean body weight of the restricted rats was significantly lower during the entire 
experiment, even at the end of the 3-week HF ad libitum refeeding period (weeks 12-14).  
3.1.2 Amylin sensitivity in DIO and food-restricted rats 
Trial 1 
Figure 1B shows the effect of acute peripheral amylin in rats maintained on the different 
feeding regimens for two weeks. The rats were injected in a crossover manner with 
either saline or a dose of 5µg/kg amylin with 2 days in between trials. With the exception 
of the restricted group, where amylin only caused a slight decrease in eating, amylin-
treated rats showed a significant reduction in energy intake, as compared with the saline 
controls, at 60 and 120 min after injection. At this time point, the body weight between ad 
libitum chow and HF rats did not differ. 
Trial 2 
Rats were tested again one week later (week 3) for their response to a higher dose of 
amylin (20µg/kg).  The effects on eating were similar to trial 1 in that amylin significantly 
reduced eating in chow and high-fat rats but not in restricted rats; the latter group again 
only showed a slight tendency to eat less after amylin (Fig. 1C). Body weight was 
significantly lower in restricted than in the chow or HF rats, but did not differ between the 
latter two groups. 
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Trials 3, 4, and 5 
Because one aim of the experiment was to test if amylin efficacy is modified by 
decreased body weight, and because the string drive to eat in the food-restricted group 
may have prevented amylin from decreasing food intake significantly within the 2h 
observation period in trials 1 and 2, the experimental design was changed. In trials 3 
through 5, all animals were allowed to eat for one hour prior to the amylin injection, i.e. 
during the first hour following dark onset. In trials 3 and 4, all rats were provided with 132 
kJ of food during this hour, which corresponds to approximately 20% of average daily ad 
libitum intake.  During the 1h prefeeding phase, the food-restricted group ate the entire 
132 kJ before saline or amylin treatment, while the chow controls and HF-fed rats only 
ate on average 57 and 53 kJ, respectively.  In trial 3, 20µg/kg of amylin still did not 
suppress food intake in the food-restricted rats at 60 or 120 min after administration 
(data not shown).  With the same design and when the amylin dose was increased in 
trial 4 (50µg/kg), the decrease in food intake induced by amylin in the food-restricted 
group was significant (Fig. 1D). In trial 5 (Fig. 1E), in which all groups were pre-fed with 
the same amount of food (50 kJ), and despite giving the relatively high dose of 50µg/kg 
amylin, the amylin effect disappeared, i.e., no significant decrease in food intake was 
observed in the food-restricted group.  In each of these trials, the chow- and HF-fed 
groups continued to show a similar and strong anorectic response to acute amylin. 
Trial 6 
For the final trial, the restricted animals were refed ad libitum with the HF diet; the chow 
and HF ad libitum fed groups of rats were fed as before. Given on days 3 and 4 following 
the switch to HF diet, a low dose of amylin (5µg/kg) significantly reduced food intake in 
the chow-fed group only (Fig. 1F). Interestingly, the anorectic effect of amylin in both 
high fat groups was not significant even though the absolute reduction in eating 
appeared to be similar across groups; when tested a few days later, the same dose of 
amylin again did not reduce eating significantly in the HF ad libitum group of rats (results 
not shown). It is important to note that the average body weight was significantly 
different between all groups at this time point, i.e. body weight in the HF group was 
significantly higher than in the chow group.   
3.1.2 Effects of HF and food-restriction on hormone levels and body composition 
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Table 1 shows basal concentrations of amylin, leptin, and insulin in fasted rats during 
weeks 9 and 14.  In week 9, rats fed HF demonstrated significantly elevated levels of 
amylin and leptin, when compared to chow-fed or food-restricted rats. Chow-fed and 
restricted rats did not differ even though restricted rats weighed significantly less. 
Furthermore, insulin levels were significantly higher in HF- and chow-fed rats compared 
to restricted rats.  In week 14 (note that the previously restricted rats had been switched 
to HF diet 3 weeks earlier), the differences in amylin and insulin levels were no longer 
detectable, despite a significant difference in body weight between formerly restricted 
and chow-fed or HF-fed rats. At this time point, circulating leptin was still higher in the 
HF group compared to the chow controls, but there was no significant difference in leptin 
levels between the HF group, which had been maintained on HF diet for 14 weeks, and 
the previously restricted group, which had only been on HF for 3 weeks.  
Average body composition of the three groups at the time of sacrifice (week 14), as 
determined by CT scan, is also shown in Table 1. There was no significant difference in 
total body fat mass between the HF and the previously restricted group, but both groups 
had significantly higher total body fat than the chow-fed controls. Similarly, no difference 
in the subcutaneous fat mass was detected between the high fat and previously 
restricted group, but both groups had significantly higher levels compared to the chow-
fed group. Comparison of total intra-abdominal fat mass revealed significantly higher 
amounts in HF-fed rats compared to the other two groups, and the previously restricted 
rats also had significantly more intra-abdominal adipose tissue compared to chow-fed 
controls. 
3.2 Experiment Two  
3.2.1 Effects of chronic amylin infusion on body weight and basal hormone levels 
Figure 2A shows the average percentage of body weight gain under the influence of two 
doses of chronic amylin treatment (5 and 10µg/kg/day) compared to control animals 
receiving saline. Body weight was set to 100% at the beginning of each of the three 
infusion weeks, and all data were combined across the three weeks and the three 
infusion groups. Although there was no significant difference among the three groups, 
control animals gained slightly more weight than the amylin treated rats. Hence, there 
was a tendency that body weight gain was inversely correlated to the amylin dose. We 
observed a similar tendency for decreased weekly food intake following 7-day amylin 
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infusion, but again no significant differences were detected between saline and amylin-
infused groups at the low doses used here (data not shown).  
Figure 2B shows the levels of basal circulating amylin as measured at the end of each of 
the three infusion weeks in ad libitum fed rats. We observed significantly higher 
circulating amylin values in rats that received chronic amylin at a dose of 5 or 10 
µg/kg/day.  For insulin and leptin, there was a tendency for amylin infusion to result in 
lower insulin and leptin levels, though no significant differences were observed (Fig. 2C 
and D). 
3.2.2 Influence of elevated amylin levels on sensitivity to acute amylin 
Figure 3 shows the effect of acute peripheral amylin on energy intake in rats with 
differing basal amylin concentrations but similar body weight. We observed no 
substantial difference in the anorectic effect of acute amylin administration dependent on 
the basal amylin levels. Across all groups, the higher the dose of the acute amylin 
treatment, the larger the acute anorectic effect of amylin.  
More precisely, at all time points and in all infusion groups energy intake was 
significantly lower following an acute injection of 20µg/kg amylin than in the saline-
injected control group. In rats with the 5µg/kg/day minipumps, we also saw a significant 
decrease in energy intake after 5µg/kg at 30 and 60min post-treatment. The main 
difference post acute amylin treatment was observed after two hours, where 5µg/kg 
amylin significantly decreased food intake in the control group, but not in the 5µg/kg/day 
nor the 10µg/kg/day infusion groups. 
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DISCUSSION 
The aims of this study were to investigate the influence of  body weight, exposure to a 
HF diet, and hyperamylinemia on the sensitivity to acute amylin injections in rats. The 
results of our studies suggest three main points. First, the suppression of food intake by 
a variety of amylin doses was comparable between rats fed chow or HF diet for up to 10 
weeks. Second, maintenance on a HF diet for longer duration and resulting obesity, only 
slightly attenuated the anorectic response to acute amylin. Finally, we observed no 
marked changes in amylin sensitivity in lean, chow fed rats with induced 
hyperamylinemia. 
5.1 Amylin-induced suppression of energy intake is decreased after 11-week 
maintenance on high fat diet 
To test the hypothesis that amylin sensitivity is inversely correlated with body weight or 
adiposity, we investigated if the effect of acute amylin to reduce eating is altered in DIO 
or food-restricted rats. These obese and lean rodent models were validated by 
measurement of the adiposity signals amylin, leptin and insulin 9 and 14 weeks after 
exposure to the HF diet, and by directly assessing body composition when terminating 
the study in week 14, using CT. It is known that elevated fasting leptin and insulin levels 
reflect increased adipose mass [1, 2], at least under relatively weight stable conditions 
[21]. Furthermore, Pieber and colleagues showed that similar to leptin and insulin, the 
basal circulating level of amylin also correlates positively with adipose mass when 
measured across individuals [10]. Consistent with these reports, we observed that after 
9 weeks on the HF diet, rats exhibited significant increases in circulating fasting amylin 
and leptin levels, compared to the chow-fed rats. Unexpectedly, we did not observe an 
effect of the HF diet-induced weight gain on fasting insulin levels. By the end of the 
experiment in week 14, the HF group still showed higher leptin levels than the chow 
control group, and terminal body composition analysis showed significant increases in 
total adipose tissue, intra-abdominal adipose tissue, and subcutaneous adipose tissue in 
HF fed rats compared to chow fed rats. Even though it would have been preferable to 
assess the development of obesity and associated adiposity signals at more time points, 
most of our data are in general agreement with the expected changes and corroborate 
the successful induction of DIO.   
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Rats restricted to 80% of the control food intake had significantly lower body weight than 
the other two groups during the entire experiment. This difference also remained 
significant during the refeeding phase, i.e. when the previously restricted rats were fed 
HF diet ad libitum for 3 weeks following the 11 week period of food restriction. These 
findings are consistent with previous studies showing that following prolonged food 
restriction, rats maintained a body weight that was lower than the pre-restriction baseline, 
even after ad libitum refeeding for as long as four months [23].  In addition to lower body 
weight, at 9 weeks the food restricted group had lower leptin, insulin, and amylin levels 
compared to HF fed rats, and lower insulin levels than the chow controls. The three 
week HF refeeding phase in the previously restricted rats had dramatic effects on 
circulating hormones (see also [21]) and body composition. Interestingly, by week 14, 
there was no difference between the circulating leptin levels of the previously restricted 
group and the HF group, despite the marked difference in body weight (HF: 533.5 ± 8.4g 
vs. [previously] Restr: 455.3 ± 10.5g). There were also no differences in total nor 
subcutaneous fat mass between the previously-restricted rats and the rats maintained 
on HF for the entire 14 weeks, which is consistent with the leptin values of the two 
groups observed at the termination of the study. Only the intra-abdominal adipose fat 
mass of the previously-restricted group remained lower compared to the HF fed rats. 
Thus, following 3 weeks of HF refeeding, the previously restricted rats nearly reached 
the same level of total body fat mass as observed in the rats fed the HF diet ad libitum 
for 14 weeks. Furthermore, the increase in body weight during the 3 weeks of ad libitum 
HF feeding appears to be largely due to an accrual of body fat and not lean mass.  Once 
again, our results are reminiscent of those reported by Brownlow and colleagues, who 
observed that following a 4-month refeeding period, rats that had been food restricted to 
50% for two months had a greater body fat percentage than ad libitum fed control rats 
[23], and who suggested that following food restriction for an extended period, rats 
develop efficient fat-depositing mechanisms which lead to rapid weight gain once food is 
provided ad libitum. Unfortunately, because body composition was not assessed 
between the food restriction and HF refeeding phases, it is not clear if the previously-
restricted rats gained more subcutaneous adipose tissue than intra-abdominal adipose 
tissue during refeeding, or if they had disproportionately lost mass from these depots 
during food restriction.  Reports have demonstrated that intra-abdominal fat depots are 
more responsive than subcutaneous adipose tissue during periods of caloric restriction 
[24, 25]. This supports the notion that food restricted rats did not necessarily gain more 
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subcutaneous adipose tissue during refeeding, but actually had lost a higher proportion 
of intra-abdominal adipose tissue during the prior restriction phase.   
Validation of the obese and lean phenotypes, even though only performed at specific 
time points and not continuously throughout the development of obesity, assists us in 
drawing conclusions from the acute amylin feeding trials. In the first 10 weeks of the 
experiment, we observed significant and similar decreases in food intake following 
amylin injection in rats on the chow control diet and in rats receiving the HF diet ad 
libitum. In a study of shorter duration, Covasa and Ritter had observed a similar effect of 
exogenous amylin in rats fed a HF (approx. 75% by energy) diet for three weeks; there 
was no difference in the acute anorectic effect of amylin between animals adapted to 
either a low or high fat diet [8]. Interestingly, using the same paradigm, there was a 
significant attenuation of the CCK effect in Sprague-Dawley rats after maintenance on 
the HF diet.  While the highest dose of CCK tested (1µg/kg) produced a reduction of 
food intake that did not differ between low- and high-fat fed rats, lower doses of CCK, 
while still effective in HF-fed rats, were significantly less powerful at reducing food intake, 
compared to low fat-fed rats.  
After 11 weeks on the HF diet, rats showed a slightly decreased response to a low dose 
of amylin, which was no longer significant, whereas the chow control group still ate 
significantly less after amylin treatment. This result suggests that long-term maintenance 
on the high fat diet may eventually attenuate the anorectic effect of acute amylin. Clearly, 
experiments using multiple doses of amylin and performed under different experimental 
conditions will be necessary to demonstrate possible amylin resistance. 
The change in sensitivity could either be the result of the diet itself, or the result of the 
increase in body weight, body fat mass, or circulating hormones or metabolites that 
resulted from the HF intake or ensuing obesity. Because we did not see any decrease in 
amylin sensitivity after HF feeding for the first 10 weeks, it seems unlikely that the 
change in amylin sensitivity would be due solely to the fat content of the diet; otherwise, 
a decrease in amylin sensitivity would very likely be anticipated earlier in the study, such 
as is e.g. the case for insulin [26] or leptin [27]. It is more probable that a change in 
amylin sensitivity would be based on the resulting change in body weight or body 
composition or, possibly, hormone or metabolite levels that differ between obese and 
leaner rats. This idea is supported by the fact that the point in time when the anorectic 
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effect of amylin was no longer significant in the HF group corresponded with a highly 
significant difference in body weight between the HF and chow fed groups.  The change 
in amylin sensitivity also followed elevated leptin and amylin levels observed in week 9. 
Still, the exact mechanism by which DIO may reduce sensitivity to amylin remains 
unclear.  While elevated levels of circulating amylin do not appear to be a main 
contributor to this effect (discussed in section 5.2), at this time, we can only speculate 
that elevated leptin levels, or a potential increase in plasma metabolites (e.g., free fatty 
acids or triglycerides, which were not measured in this study), might be involved in 
attenuated amylin sensitivity following DIO [28]. Further experiments, performed under a 
variety of dietary and metabolic conditions, will be necessary to demonstrate possible 
amylin resistance. 
Unlike the HF fed rats, food-restricted rats only responded to an acute amylin injection 
when the animals were pre-fed for one hour with 50% of their daily amount of food and  
when they received a comparably high dose of amylin (50µg/kg). Because the anorectic 
effect was only observed after pre-feeding, we believe that the drive to eat after 
prolonged food restriction may simply have been too strong, and likely masked the 
anorectic properties of amylin. The phenomenon was still apparent in the last acute 
amylin trial, i.e. 3 to 4 days after allowing the (previously) restricted rats ad libitum 
access to HF food. Overall, we therefore believe that decreased body weight, at least 
under these test conditions of habituation to dark onset presentation of food and acute 
amylin injections, does not appear to reveal increased sensitivity to amylin.  
Unfortunately, it was not possible in the frame of this study to test other satiating 
hormones, like CCK, under these chronically restricted conditions. Thus, we cannot 
conclude that our observation was specific to amylin or that it was part of a more 
generalized phenomenon. It is well-established, however, that food deprivation produces 
a number of neural and physiological responses aimed at stimulating eating and 
correcting for the impinging energy deficit; these responses possibly contributed to our 
findings. Plasma insulin is one of the signals that is reduced in food-deprived rats, which 
was also exhibited in this study following 9 weeks of food-restriction, to allow the 
mobilization of stored energy from adipose tissue and to promote gluconeogenesis [29]. 
Data demonstrate that amylin and insulin interact to suppress food intake in rats, 
suggesting that the presence of very low insulin levels below a certain range may have 
prevented the acute anorectic response of amylin [30].  Additionally, the concentration of 
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the hunger signal ghrelin is known to increase after fasting and it is also known that a 
loss in body weight leads to an increase in circulating ghrelin [31, 32]. The upregulation 
of these and other mechanisms in food restricted rats may explain why we did not 
observe an anorectic effect of acute amylin in the chronically restricted animals, at least 
with amylin doses that reduce eating in non-restricted animals. 
Another contribution to changes in amylin sensitivity in obese and lean rats could be the 
interaction between amylin and leptin. It is known that a co-infusion of amylin and leptin 
reduces body weight and adiposity synergistically in DIO prone rats [22]. Additionally, it 
has been shown that peripheral administration of amylin restores leptin sensitivity in 
obese rats and humans [33]. These findings suggest that an interaction exists between 
exogenous amylin and the prevailing circulating leptin values. It is possible that 
exogenous amylin only shows its anorectic effect in a certain range of circulating leptin 
levels. Although speculative, this may explain why we observed a reduced sensitivity to 
the anorectic activities of acute amylin in both obese rats, with high circulating leptin 
levels, and in restricted rats, with very low circulating leptin levels [28]. The fact that 
obese Zucker rats, which lack functional leptin receptors, show decreased 
responsiveness to CCK [34], supports the notion that the absence of normal leptin 
signalling can modify the effectiveness of satiating signals, such as CCK and perhaps 
also amylin. 
5.2 Hyperamylinemia alone does not cause amylin insensitivity 
In experiment one, we observed a slight decrease in amylin sensitivity after long-term 
exposure of rats to a HF diet, which resulted in increased body weight, fat mass, 
hyperleptinemia and hyperamylinemia. Because it remained unclear which of these 
factors may primarily contribute to decreased amylin sensitivity after prolonged high fat 
consumption, we investigated whether hyperamylinemia alone, independent of other 
obesity-related factors, causes a decrease in the sensitivity to acute amylin 
administration. In addition to becoming obese, hyperinsulinemic and hyperleptinemic 
DIO rats fed a high energy diet also show a decrease in insulin and leptin sensitivity, 
respectively [35, 36]. It was also recently shown that hyperleptinemia is necessary for 
the full development of leptin resistance [7]. Because obesity is also associated with 
hyperamylinemia, we therefore tested whether elevated levels of circulating amylin might 
contribute to decreased amylin sensitivity. 
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By chronically infusing amylin at 5 or 10µg/kg/day for seven days, we achieved average 
basal circulating amylin levels of  approximately 30 to 40 pM, which were significantly 
higher than the baseline concentration in the lean rats in this experiment (16.5  2.7 pM), 
and which were in the range of obese rats in the fed state (Boyle et al, unpublished 
observations). In contrast to our hypothesis, we observed no marked difference in amylin 
sensitivity among the groups with different background circulating amylin levels. Thus, 
regardless of the level of circulating amylin, acute peripheral amylin decreased food 
intake in a dose-dependent manner, and this effect was similar under all conditions. 
These results suggest that hyperamylinemia alone, without the impact of obesity or 
obesity-associated parameters, does not cause a marked decrease in (acute) amylin 
sensitivity. It is important to note, however, that two hours after acute amylin treatment 
with a dose of 5µg/kg, the anorectic effect of acute amylin was no longer detected in the 
animals with the moderate (~30pM) and high (~40pM) circulating baseline amylin levels, 
though the effect was present in the control rats receiving saline infusion. This suggests 
the presence of a subtle reduction in amylin sensitivity in rats receiving chronic amylin 
infusion, and that after two hours the concentration of the acutely administered amylin 
was likely too low to induce a further decrease in food intake in animals that already 
have elevated baseline circulating amylin. Therefore, it is possible that by administering 
a lower dose of acute exogenous amylin, a decrease in amylin sensitivity might have 
been uncovered at earlier time points.  
Amylin activation of calcitonin receptors (CT-R) in the area postrema (AP) is considered 
the main mechanism mediating amylin’s anorectic effects [37-39]. The present results 
suggest that it is unlikely that the expression of CT-Rs in the AP is downregulated 
following 7-day infusion of physiological doses of amylin. The results also indicate that 
this degree of hyperamylinemia has little effect on the amylin signaling pathways which 
control feeding behavior [28]. Based on these data, one could also speculate that 
decreased sensitivity occurs independently of amylin receptor dysfunction in the AP. We 
have collected some preliminary evidence to support this idea, because only little 
difference was observed between amylin-induced cFos expression in the AP of lean and 
obese rats, however, additional studies are needed [28].  
Previous studies had shown that chronic subcutaneous or third ventricular infusion of 
amylin produced a transient,  dose-dependent decrease in daily food intake and a 
decrease in body weight gain [40, 41]. Mack and colleagues showed that amylin 
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(10µg/kg/day) infused subcutaneously for four weeks decreased food intake and body 
weight in rats fed a HF diet for five weeks [16]. Consistent with these findings, our rats 
receiving exogenous amylin showed a tendency to gain less body weight over the one 
week infusion period, and the effect seemed to be dose-dependent. However, probably 
because of the low doses of administered amylin and the short duration of the study, the 
difference across the groups for the effect on body weight gain or baseline food intake 
did not reach significance. In a similar study, the minimal effective dose for suppressing 
daily food intake was 32.3µg/kg/day (7pmol/kg/min) which produced plasma amylin 
levels of approximately 80 pM [42], i.e. much higher than the physiological levels 
observed in DIO rats and much higher than the concentrations in our experiment. 
Though our elevated levels of amylin, which were still in the physiological range, did not 
produce dramatic changes in body weight and food intake, our results do provide further 
evidence that amylin may play a role in the long-term control of energy balance, similar 
to well known adiposity signals, like insulin and leptin [43]. 
In our experiments, it was important to consider what effect chronic hyperamylinemia 
might have on circulating levels of insulin or leptin. It had been previously reported that 
insulin secretion is increased by the administration of an amylin antagonist in isolated rat 
islets [44], suggesting that an interaction exists between amylin and insulin secretion. 
This idea was further supported by findings showing that insulin secretion in the rat 
pancreas was suppressed by high doses of amylin [45]. Additionally, Gebre-Medhin and 
colleagues observed that amylin deficient mice showed increased plasma insulin 
responses following glucose administration, whereas baseline insulin and glucose levels 
were normal [46]. Together, these data demonstrate that high amylin levels may 
feedback to suppress insulin secretion. Our data are also consistent with these reports. 
Though physiological doses of hyperamylinemia did not significantly suppress circulating 
insulin in this study, we observed that the higher amylin dose had a tendency to lower 
insulin concentration. Furthermore, because of the known interaction between amylin 
and leptin [22, 33], we determined whether an increase of amylin, independent of obesity, 
alters circulating leptin levels.  Again we observed that as circulating amylin levels 
increased, there was a trend toward a decrease in leptin levels. Whether this was a 
direct effect of the hyperamylinemia cannot be addressed; it is quite possible that the 
slight lowering of leptin levels was a result of slightly decreased weight gain induced by 
amylin infusion, rather than a direct effect of hyperamylinemia on the leptin concentration. 
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5.3 Summary 
Our study tested the ability of acute amylin to suppress food intake and its modulation by 
the metabolic status in the rat. While up to 10 weeks of HF feeding did not seem to 
reduce amylin’s acute anorectic action in rats, extended ad libitum exposure of rats to 
the HF diet and ensuing obesity may result in a reduced amylin effect; even though there 
still appeared to be a reduction in food intake, the effect was no longer significant. 
However, experiments with additional doses of amylin will be necessary to demonstrate 
possible amylin resistance. We also found that rats that were chronically food restricted 
to 80% of their ad libitum intake appeared to be resistant to a short term reduction in 
eating under our experimental conditions and induced by acute amylin injection; the 
drive to eat at the time when the daily food ration was presented was most likely too 
strong and hence overcame the satiating signal generated by the (single) amylin 
injection. Interestingly, even during the initial phase of catch up growth when the 
previously restricted rats were allowed ad libitum access to HF food, acute amylin did 
not significantly reduce eating in these rats. Food restricted rats did react to amylin, 
though, if prefed prior to injection. Defining the exact mechanism underlying these 
phenomena will require follow up studies. Finally, the last experiment indicated that even 
in the presence of hyperamylinemia in a concentration range typical for obese rats, 
acute amylin was able to reduce short-term food intake. Hence, chronic elevation of the 
circulating amylin concentration does not seem to result in downregulation of the amylin 
signaling system. Overall, our studies provide new information in terms of amylin’s 
effectiveness to reduce eating under conditions of HF induced DIO or chronic 
hyperamylinemia. 
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FIGURE LEGENDS 
 
FIGURE 1: Effects of high fat feeding and food restriction on body weight 
development and amylin sensitivity in acute feeding trials. 
(A) Mean (± SEM) body weight of rats maintained on standard chow (Chow; white 
circles), 60% high fat diet (HF; gray triangles) or restricted to 80% intake of the chow ad 
libitum group (Restr; black squares). At the start of week 12, Restr rats were given ad 
libitum access to HF diet. Solid arrows indicate feeding trials and the corresponding 
dose of amylin administered (g/kg); dashed arrows indicate blood sampling for 
hormone analysis. Body adiposity was determined by CT scan following sacrifice in 
week 14. Mean (± SEM) cumulative energy intake 60 and 120 minutes after saline or 
amylin injection in rats maintained on chow, HF, or 80% food restriction for 2 weeks (B; 5 
g/kg amylin), 3 weeks (C; 20 g/kg amylin), 7 weeks (D; 50g/kg amylin), 10 weeks (E, 
50g/kg amylin), and 12 weeks (F, 5g/kg). Symbols in A denote significant differences 
between the three diet groups; + chow vs restricted, °chow vs high fat, * high fat vs 
restricted; Symbols in B-F denote significant differences between saline- and amylin-
treated groups within diet groups; *p<0.05, **p<0.01, ***p<0.001. 
 
FIGURE 2: Effects of 7-day amylin infusion on body weight gain and circulating 
hormone levels. 
(A) Mean (± SEM) percent body weight gain in rats (n=20) implanted with osmotic 
minipumps infusing NaCl (white circles), 5μg/kg/day amylin (gray triangles) or 
10μg/kg/day amylin (black squares) for 7 days. Mean (± SEM) amylin (B), insulin (C), 
and leptin (D) levels measured on day 7 of NaCl (white bars), 5μg/kg/day amylin (gray 
bars) or 10μg/kg/day amylin (black bars) infused rats. Symbols denote significant 
differences between infusion groups; *p<0.05, **p<0.01. 
 
FIGURE 3: Effect of 7-day amylin infusion on amylin sensitivity in acute feeding 
trials. 
Mean (± SEM) cumulative energy intake 30, 60 and 120 minutes after acute saline 
(white bars) 5μg/kg amylin (gray bars) or 20μg/kg amylin (black bars) injection in rats 
implanted with a osmotic minipump infusing either saline (A), 5μg/kg/day amylin (B) or 
10μg/kg/day amylin (C). Symbols denote significant differences between saline- and 
amylin-treatment within infusion groups; *p<0.05, **p<0.01, ***p<0.001  
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TABLE LEGEND 
TABLE 1: Effects of high fat feeding and food restriction (and subsequent HF 
refeeding) on circulating hormone levels and body adiposity 
Mean ± SEM leptin, insulin and amylin levels measured in rats maintained on chow, high 
fat diet (HF), or 80% food restriction (Restr) for 9 weeks. Hormones were assessed 
again after 14 weeks, at which time previously restricted (Prev Restr) rats had been 
switched to HF-diet presented ad libitum for 3 weeks. After sacrifice in week 14, total 
(TAT), subcutaneous (SAT), and intra-abdominal adipose tissue (IAAT) were assessed 
by CT scan. Letters denote significant differences compared to a: Chow, b: HF, and c: 
Restr or Prev Restr groups, where P<0.05. 
